https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-03-31 / Vaccine 2005 Mar;23(19):2439-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-03-31 / Vaccine 2005 Mar;23(19):2439-532005-03-31 00:00:002020-06-23 09:38:03T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-03-01 / Cancer Gene Ther. 2005 Mar;12(3):295-303
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-03-01 / Cancer Gene Ther. 2005 Mar;12(3):295-3032005-03-01 00:00:002020-06-23 09:38:35Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-02-01 / Int. J. Oncol. 2005 Feb;26(2):431-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-02-01 / Int. J. Oncol. 2005 Feb;26(2):431-92005-02-01 00:00:002020-06-23 09:39:16Selective gene transfer to tumor cells by recombinant Newcastle Disease Virus via a bispecific fusion protein
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / J. Virol. 2005 Jan;79(1):581-91
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / J. Virol. 2005 Jan;79(1):581-912005-01-01 00:00:002005-01-01 00:00:00Effects of febrile temperature on adenoviral infection and replication: implications for viral therapy of cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-11-01 / Cancer Res. 2004 Nov;64(21):8057-61
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-11-01 / Cancer Res. 2004 Nov;64(21):8057-612004-11-01 00:00:002020-06-23 09:39:52Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-10-30 / Cancer Immunol. Immunother. 2005 Jun;54(6):587-98
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-10-30 / Cancer Immunol. Immunother. 2005 Jun;54(6):587-982004-10-30 00:00:002020-06-23 09:40:23Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-09-27 / J. Clin. Oncol. 2004 Nov;22(21):4272-81
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-09-27 / J. Clin. Oncol. 2004 Nov;22(21):4272-812004-09-27 00:00:002020-06-23 09:41:00Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-08-01 / Int. J. Oncol. 2004 Aug;25(2):293-302
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-08-01 / Int. J. Oncol. 2004 Aug;25(2):293-3022004-08-01 00:00:002020-06-23 09:41:28High cell surface expression of Newcastle disease virus proteins via replicon vectors demonstrates syncytia forming activity of F and fusion promotion activity of HN molecules
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-03-01 / Int. J. Oncol. 2004 Mar;24(3):623-34
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-03-01 / Int. J. Oncol. 2004 Mar;24(3):623-342004-03-01 00:00:002020-06-23 09:42:15Importance of serine 200 for functional activities of the hemagglutinin-neuraminidase protein of Newcastle Disease Virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-03-01 / J. Neurooncol. 2004 Mar-Apr;67(1-2):83-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-03-01 / J. Neurooncol. 2004 Mar-Apr;67(1-2):83-932004-03-01 00:00:002019-02-15 09:00:18MTH-68/H oncolytic viral treatment in human high-grade gliomas
